NICE approves more treatments for MS

Beta interferons and glatiramer acetate are now options for routine NHS prescribing in relapsing-remitting multiple sclerosis (MS) after companies reduce prices.

by Sandhiya Sodha
MS is a chronic, lifelong and disabling condition affecting the brain and spinal cord. It is estimated that around 116,000 people in England are affected, of whom about 40,000 have relapsing-remitting MS. | ZEPHYR/SCIENCE PHOTO LIBRARY
MS is a chronic, lifelong and disabling condition affecting the brain and spinal cord. It is estimated that around 116,000 people in England are affected, of whom about 40,000 have relapsing-remitting MS. | ZEPHYR/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package